Daudén E, Carretero G, Rivera R, et al. - Researchers conducted the study for characterizing the safety findings of systemic drugs (acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, ustekinumab) used for the treatment of moderate-to-severe psoriasis in patients (n = 2,845) involved in Biobadaderm. Using methotrexate as reference, the incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug were determined by means of a prospective cohort. According to findings, ustekinumab and secukinumab had the lowest rate of adverse events for several of the system organ class with statistically significant reduced rate ratio (IRR<1), on the other hand, cyclosporine and infliximab had the highest, with increased rate ratio (IRR ≥ 5). In the real-life setting, the data provide comparative safety information which may help clinicians choose between available items.